Connection

CHRISTINE BEETON to Humans

This is a "connection" page, showing publications CHRISTINE BEETON has written about Humans.
Connection Strength

0.267
  1. A bioengineered probiotic for the oral delivery of a peptide Kv1.3 channel blocker to treat rheumatoid arthritis. Proc Natl Acad Sci U S A. 2023 01 10; 120(2):e2211977120.
    View in: PubMed
    Score: 0.023
  2. Differences in ion channel phenotype and function between humans and animal models. Front Biosci (Landmark Ed). 2018 01 01; 23(1):43-64.
    View in: PubMed
    Score: 0.016
  3. KCa1.1 channels as therapeutic targets for rheumatoid arthritis. Expert Opin Ther Targets. 2017 12; 21(12):1077-1081.
    View in: PubMed
    Score: 0.016
  4. Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog. Clin Immunol. 2017 07; 180:45-57.
    View in: PubMed
    Score: 0.015
  5. Detection of Matrix Metalloproteinases by Zymography. Methods Mol Biol. 2017; 1579:231-244.
    View in: PubMed
    Score: 0.015
  6. Functional KCa1.1 channels are crucial for regulating the proliferation, migration and differentiation of human primary skeletal myoblasts. Cell Death Dis. 2016 10 20; 7(10):e2426.
    View in: PubMed
    Score: 0.015
  7. Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma. J Biol Chem. 2014 May 02; 289(18):12623-32.
    View in: PubMed
    Score: 0.012
  8. Blocking KCa3.1 channels increases tumor cell killing by a subpopulation of human natural killer lymphocytes. PLoS One. 2013; 8(10):e76740.
    View in: PubMed
    Score: 0.012
  9. Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases. Inflamm Allergy Drug Targets. 2011 Oct; 10(5):313-21.
    View in: PubMed
    Score: 0.010
  10. Quantitative measurement of GLUT4 translocation to the plasma membrane by flow cytometry. J Vis Exp. 2010 Nov 07; (45).
    View in: PubMed
    Score: 0.010
  11. Discovery on Target 2007--CHI's Fifth Annual Conference. Ion channels. IDrugs. 2007 Dec; 10(12):851-4.
    View in: PubMed
    Score: 0.008
  12. The D-diastereomer of ShK toxin selectively blocks voltage-gated K+ channels and inhibits T lymphocyte proliferation. J Biol Chem. 2008 Jan 11; 283(2):988-97.
    View in: PubMed
    Score: 0.008
  13. Enrichment of NK cells from human blood with the RosetteSep kit from StemCell technologies. J Vis Exp. 2007; (8):326.
    View in: PubMed
    Score: 0.008
  14. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci U S A. 2006 Nov 14; 103(46):17414-9.
    View in: PubMed
    Score: 0.007
  15. Potassium channels, memory T cells, and multiple sclerosis. Neuroscientist. 2005 Dec; 11(6):550-62.
    View in: PubMed
    Score: 0.007
  16. In vivo expansion of gene-targeted hepatocytes through transient inhibition of an essential gene. Sci Transl Med. 2025 Feb 12; 17(785):eadk3920.
    View in: PubMed
    Score: 0.007
  17. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol. 2005 Apr; 67(4):1369-81.
    View in: PubMed
    Score: 0.007
  18. A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes. J Biol Chem. 2003 Mar 14; 278(11):9928-37.
    View in: PubMed
    Score: 0.006
  19. Syndecan-2 regulates PAD2 to exert antifibrotic effects on RA-ILD fibroblasts. Sci Rep. 2022 02 18; 12(1):2847.
    View in: PubMed
    Score: 0.005
  20. AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9. Mol Ther. 2020 Jun 03; 28(6):1432-1441.
    View in: PubMed
    Score: 0.005
  21. Inhibition of Upf2-Dependent Nonsense-Mediated Decay Leads to Behavioral and Neurophysiological Abnormalities by Activating the Immune Response. Neuron. 2019 11 20; 104(4):665-679.e8.
    View in: PubMed
    Score: 0.004
  22. KCa1.1 and Kv1.3 channels regulate the interactions between fibroblast-like synoviocytes and T lymphocytes during rheumatoid arthritis. Arthritis Res Ther. 2019 01 07; 21(1):6.
    View in: PubMed
    Score: 0.004
  23. Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation. Circulation. 2018 11 13; 138(20):2227-2242.
    View in: PubMed
    Score: 0.004
  24. KCa1.1 channels regulate ?1-integrin function and cell adhesion in rheumatoid arthritis fibroblast-like synoviocytes. FASEB J. 2017 08; 31(8):3309-3320.
    View in: PubMed
    Score: 0.004
  25. Different expression of ? subunits of the KCa1.1 channel by invasive and non-invasive human fibroblast-like synoviocytes. Arthritis Res Ther. 2016 05 10; 18(1):103.
    View in: PubMed
    Score: 0.004
  26. The cation channel Trpv2 is a new suppressor of arthritis severity, joint damage, and synovial fibroblast invasion. Clin Immunol. 2015 Jun; 158(2):183-92.
    View in: PubMed
    Score: 0.003
  27. Big Potassium (BK) ion channels in biology, disease and possible targets for cancer immunotherapy. Int Immunopharmacol. 2014 Oct; 22(2):427-43.
    View in: PubMed
    Score: 0.003
  28. Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases. FASEB J. 2014 Sep; 28(9):3952-64.
    View in: PubMed
    Score: 0.003
  29. Ion channels and anti-cancer immunity. Philos Trans R Soc Lond B Biol Sci. 2014 Mar 19; 369(1638):20130106.
    View in: PubMed
    Score: 0.003
  30. A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3. FEBS Lett. 2012 Nov 16; 586(22):3996-4001.
    View in: PubMed
    Score: 0.003
  31. Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease. J Pharmacol Exp Ther. 2012 Sep; 342(3):642-53.
    View in: PubMed
    Score: 0.003
  32. Vm24, a natural immunosuppressive peptide, potently and selectively blocks Kv1.3 potassium channels of human T cells. Mol Pharmacol. 2012 Sep; 82(3):372-82.
    View in: PubMed
    Score: 0.003
  33. KCa1.1 potassium channels regulate key proinflammatory and invasive properties of fibroblast-like synoviocytes in rheumatoid arthritis. J Biol Chem. 2012 Feb 03; 287(6):4014-22.
    View in: PubMed
    Score: 0.003
  34. Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis. Nat Commun. 2011; 2:334.
    View in: PubMed
    Score: 0.002
  35. Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes. Mol Pharmacol. 2009 Apr; 75(4):762-73.
    View in: PubMed
    Score: 0.002
  36. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci U S A. 2005 Aug 02; 102(31):11094-9.
    View in: PubMed
    Score: 0.002
  37. Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol. 2004 Jun; 65(6):1364-74.
    View in: PubMed
    Score: 0.002
  38. K+ channels as targets for specific immunomodulation. Trends Pharmacol Sci. 2004 May; 25(5):280-9.
    View in: PubMed
    Score: 0.002
  39. Potassium channels as therapeutic targets for autoimmune disorders. Curr Opin Drug Discov Devel. 2003 Sep; 6(5):640-7.
    View in: PubMed
    Score: 0.001
  40. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J Clin Invest. 2003 Jun; 111(11):1703-13.
    View in: PubMed
    Score: 0.001
  41. Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J Immunol. 2001 Jan 15; 166(2):936-44.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.